Changsha Caoquan Technology

About Changsha Caoquan Technology test results from Finnrick

Changsha Caoquan Technology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 1 peptide and 4 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Changsha Caoquan Technology peptides in this dataset are Retatrutide (4 tests), Tesamorelin (0 tests) and Tirzepatide (0 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 4 recent tests.